SESN1 and neoplasm: While, patients with poor prognosis (age ≥18 months, MYCN‐amplification, high risk, stage3 and stage4, unfavor histopathology (UFH), with tumor progression, and death for disease) had significantly lower expression of SESN1 than those with good prognosis (p < 0.001) (Figure 5F and Figure S3A).